Sculptor Capital’s Ibere Pharmaceuticals IBER Stock Holding History

Sculptor Capital’s Portfolio IBER Stock Details IBER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-425,000	Closed	-$4.29M	–	846
2022 Q4	$4.29M	Hold	425,000	–	–	0.07%	275
2022 Q3	$4.21M	Hold	425,000	–	–	0.05%	400
2022 Q2	$4.17M	Hold	425,000	–	–	0.04%	451
2022 Q1	$4.17M	Hold	425,000	–	–	0.03%	478
2021 Q4	$4.13M	Hold	425,000	–	–	0.04%	430
2021 Q3	$4.12M	Hold	425,000	–	–	0.03%	371
2021 Q2	$4.11M	Buy	+425,000	New	+$4.14M	0.03%	365

Sculptor Capital's IBER Position: Q1 2023 in Review

Sculptor Capital sold out of Ibere Pharmaceuticals (IBER) in Q1 2023, closing a stake of 425,000 shares — an estimated $4.29M sold.

Sculptor Capital first reported a position in IBER in Q2 2021 and held it in 7 quarters. The position peaked at $4.29M in Q4 2022. 0 funds tracked by Wall St. Rank hold IBER as of Q1 2023.

Sculptor Capital reported no remaining Ibere Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Sculptor Capital sold 425,000 Ibere Pharmaceuticals shares in Q1 2023, an estimated $4.29M.
Sculptor Capital first reported a position in Ibere Pharmaceuticals in Q2 2021 and held it in 7 quarters.
Sculptor Capital's Ibere Pharmaceuticals position peaked at $4.29M in Q4 2022.
0 funds tracked by Wall St. Rank held Ibere Pharmaceuticals as of Q1 2023.

Based on Sculptor Capital's 13F filing for Q1 2023, filed 16 May 2023.